



NUCLEA BIOMARKERS, LLC

For Further Information Contact
Patrick J. Muraca, President and CEO

PRESS RELEASE

Corporate Headquarters
105 South Street
Pittsfield, MA 01201
Phone: 413.749.4705
Fax: 413.445.9930
www.nucleabiomarkers.com

FOR IMMEDIATE RELEASE

**NUCLEA BIOMARKERS ANNOUNCES THAT IT HAS RECEIVED A
U.S. PATENT ON “KINASE PEPTIDES AND ANTIBODIES”**

Pittsfield, Massachusetts.....April 10, 2008.....Nuclea Biomarkers, LLC announced today that it has been accorded U.S. Patent No. 7,354,725 B2 entitled “Kinase Peptides and Antibodies,” which issued on April 8, 2008. “The issuance of this patent is an important step in the company’s multifaceted strategy for protecting its unique intellectual property assets” stated Patrick J. Muraca, President and CEO of Nuclea. “The antibodies covered by this patent are critical pieces of Nuclea’s core technology, which allows us to accurately, reproducibly and rapidly identify and quantify kinase protein expression.” Patent applications covering other aspects of the company’s technology, including its gene and protein expression technology, are pending and are being filed on a continual basis as new innovations are developed.

The issuance of this patent has major implications in the pursuit of personalized medicine. This biological technology outlined in the ‘752 patent allows Nuclea to further its mission to help select appropriate therapeutics of patients that are suffering from the metastasis of solid tumors.

Later this year, Nuclea will engage in specific pre-clinical trials to match its biologically active compounds that target Tyrosine Kinase over-expression and the detection of such over-expression using this technology.

Nuclea Biomarkers, LLC is a biotechnology services company that has developed a novel technology platform to greatly improve the efficiency of genomics pharmacogenomics and proteomics in oncology research and predictive medicine. Using the company’s extensive and growing libraries of genetic, molecular and clinical information, Nuclea is able to focus time and resources on the most promising paths for diagnosing and treating a broad range of oncologic diseases.



US007354725B2

**(12) United States Patent
Muraca****(10) Patent No.: US 7,354,725 B2
(45) Date of Patent: Apr. 8, 2008**(54) **KINASE PEPTIDES AND ANTIBODIES**WO WO 02/083933 10/2002
WO WO 03/087400 10/2003
WO WO 2004/038040 5/2004(75) Inventor: **Patrick J. Muraca**, Pittsfield, MA (US)(73) Assignee: **Nuclea Biomarkers, LLC**, Pittsfield, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **11/435,570**(22) Filed: **May 17, 2006**(65) **Prior Publication Data**

US 2006/0281111 A1 Dec. 14, 2006

Related U.S. Application Data

(60) Provisional application No. 60/682,115, filed on May 18, 2005.

(51) **Int. Cl.****G01N 33/53** (2006.01)(52) **U.S. Cl.** **435/7.1**; 435/7.2; 435/7.91; 435/7.92; 436/518; 530/387.1(58) **Field of Classification Search** 435/7.1, 435/7.2, 7.91, 7.92; 436/518; 530/387.1
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**6,001,580 A * 12/1999 Tani et al. 435/7.1
6,258,776 B1 7/2001 Hemmings et al. 514/2
7,108,992 B2 * 9/2006 Kastan et al. 435/7.4**FOREIGN PATENT DOCUMENTS**

WO WO 01/27315 4/2001

OTHER PUBLICATIONSStokoe, et al., "The substrate specificity and structure of mitogen-activated protein (MAP) kinase-activated protein kinase-2"; *Biochem J.*; (1993) 295: 843-849.Wadsworth, et al., "RWJ 67657, a Potent, Orally Active Inhibitor of p38 Mitogen-Activated Protein Kinase"; *J. Pharmacol & Experimental Therapeutics*; (1999) 291: 680-687.

International Search Report from International Application No. PCT/US06/18974 dated Jan. 16, 2007.

Clifton, et al.; "A comparison of the substrate specificity of MAPKAP kinase-2 and MAPKAP kinase-3 and their activation by cytokines and cellular stress"; *FEBS Letts.*; (1996); 392: 209-214.Leighton, et al.; "Comparison of the specificities of p70 S6 kinase and MAPKAP kinase-1 identifies a relatively specific substrate for p70 S6 kinase: the N-terminal kinase domain of MAPKAP kinase-1 is essential for peptide phosphorylation"; *FEBS Letts.*; (1995); 375: 289-293.Stokoe, et al.; "The substrate specificity and structure of mitogen-activated protein (MAP) kinase-activated protein kinase-2"; *Biochem. J.*; (1993); 296: 843-849.

Search Report dated May 17, 2006.

* cited by examiner

Primary Examiner—Long V. Le*Assistant Examiner*—Jacob Cheu(74) *Attorney, Agent, or Firm*—Paula C. Evans(57) **ABSTRACT**

The invention relates to novel kinase peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of a kinase-mediated disease, as well as for determining or monitoring the efficacy of treatment.

4 Claims, 8 Drawing Sheets